These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37630989)

  • 1. Blocking the CGRP Receptor: Differences across Human Vascular Beds.
    de Vries T; Boucherie DM; van den Bogaerdt A; Danser AHJ; MaassenVanDenBrink A
    Pharmaceuticals (Basel); 2023 Jul; 16(8):. PubMed ID: 37630989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab.
    de Vries T; Rubio-Beltrán E; van den Bogaerdt A; Dammers R; Danser AHJ; Snellman J; Bussiere J; MaassenVanDenBrink A
    Br J Pharmacol; 2024 Jun; 181(12):1720-1733. PubMed ID: 38320397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on zavegepant: the first intranasal third-generation gepant.
    Scuteri D; Tarsitano A; Tonin P; Bagetta G; Corasaniti MT
    Pain Manag; 2022 Nov; 12(8):879-885. PubMed ID: 36189708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of CGRP receptors in the human isolated middle meningeal artery.
    Gupta S; Mehrotra S; Avezaat CJ; Villalón CM; Saxena PR; Maassenvandenbrink A
    Life Sci; 2006 Jun; 79(3):265-71. PubMed ID: 16458930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
    Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
    Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.
    Moreno MJ; Abounader R; Hébert E; Doods H; Hamel E
    Neuropharmacology; 2002 Mar; 42(4):568-76. PubMed ID: 11955527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.
    Rubio-Beltran E; Chan KY; Danser AJ; MaassenVanDenBrink A; Edvinsson L
    Cephalalgia; 2020 Apr; 40(4):357-366. PubMed ID: 31674221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
    Rissardo JP; Caprara ALF
    Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity.
    Gupta S; Mehrotra S; Villalón CM; Garrelds IM; de Vries R; van Kats JP; Sharma HS; Saxena PR; Maassenvandenbrink A
    Eur J Pharmacol; 2006 Jan; 530(1-2):107-16. PubMed ID: 16375887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.
    Chan KY; Edvinsson L; Eftekhari S; Kimblad PO; Kane SA; Lynch J; Hargreaves RJ; de Vries R; Garrelds IM; van den Bogaerdt AJ; Danser AH; Maassenvandenbrink A
    J Pharmacol Exp Ther; 2010 Sep; 334(3):746-52. PubMed ID: 20573757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
    Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S
    Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of CGRP receptors mediating relaxation of the rat pulmonary artery and inhibition of twitch responses of the rat vas deferens.
    Wisskirchen FM; Burt RP; Marshall I
    Br J Pharmacol; 1998 Apr; 123(8):1673-83. PubMed ID: 9605575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.
    Woodhead JL; Siler SQ; Howell BA; Watkins PB; Conway C
    Toxicol Sci; 2022 Jun; 188(1):108-116. PubMed ID: 35556143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
    Bedrin K; Ailani J; Dougherty C
    Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice.
    Mulder IA; Li M; de Vries T; Qin T; Yanagisawa T; Sugimoto K; van den Bogaerdt A; Danser AHJ; Wermer MJH; van den Maagdenberg AMJM; MaassenVanDenBrink A; Ferrari MD; Ayata C
    Ann Neurol; 2020 Oct; 88(4):771-784. PubMed ID: 32583883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.